Aging is accompanied by changes in hematopoiesis and consequently in leukocyte phenotype and function. Although age-related changes in bone marrow hematopoiesis are fairly well documented, changes in extramedullary hematopoiesis are less well described. We observed that 18-22-mo-old mice had larger spleens than young controls and found that the enlargement was caused by increased monopoiesis. Because extramedullary hematopoiesis is often driven by inflammation, we hypothesized that the chronic, low-level inflammation that occurs with age is a causal agent in splenomegaly. To test this theory, we compared the number of monocytes in 18-mo-old tumor necrosis factor-knockout mice, which are protected from age-associated inflammation, and found that they did not have increased extramedullary monopoiesis. To determine whether increased splenic monopoiesis is caused by intrinsic changes in the myeloid precursors that occur with age or by the aging microenvironment, we created heterochronic bone marrow chimeras. Increased splenic monopoiesis occurred in old recipient mice, regardless of the age of the donor mouse, but not in young recipient mice, demonstrating that these cells respond to signals from the microenvironment. These data suggest that decreasing the inflammatory microenvironment with age would be an effective strategy for reducing inflammatory diseases propagated by cells of myeloid lineage, which increase in number with age.
Introduction
The primary niche for hematopoiesis in the body is the bone marrow; however, EMH occurs at sites such as the spleen and liver [1, 2] . EMH is a result of HSPCs that migrate from the bone marrow and seed peripheral tissues, where they proliferate locally [3, 4] . This phenomenon occurs during normal fetal development in the liver and spleen [5] but is maintained at a lower level in adulthood [6] . HSPCs are highly responsive to cues in their microenvironment (e.g., hormones [7] , metabolic products [8, 9] , inflammatory mediators [10] ). EMH occurs primarily in the spleen during infectious or inflammatory insult to the host and favors myelopoiesis over lymphopoiesis [11] [12] [13] . This process results in rapid production of myeloid cells, which have both antimicrobial and regenerative properties [1, 6] . For example, during infection with Leishmania major myeloid progenitors increase in the spleen [14] , whereas during early infection with Listeria monocytogenes inflammatory monocytes (CCR2 high Ly6C high ) accumulate in the spleen [15] [16] [17] . In contrast, during inflammatory events such as myocardial infarction, splenic EMH produces a reservoir of monocytes that are rapidly mobilized in response to myocardial infarction and facilitate healing [12, 13] . Likewise, splenic progenitors transferred from normal mice differentiate into functional islet cells when adoptively transferred into nonobese diabetic mice with type I diabetes, rescuing this autoimmune condition when accompanied by immune therapy [18, 19] .
Splenic EMH is not solely a response to inflammatory insult but has been shown to contribute to many inflammatory diseases including atherosclerosis, myelofibrosis, colitis, and cancer [12, [20] [21] [22] [23] [24] [25] . Myeloid cells, particularly monocytes and macrophages of splenic origin, are major propagators of inflammatory diseases and have been investigated as potential biomarkers in these diseases [25, 26] . In mice there are 2 monocyte subsets: Ly6C low and Ly6C high . The Ly6C low monocytes are long lived and patrol the vasculature and promote tissue healing by preferentially differentiating into macrophages with regenerative properties [27] . Conversely, Ly6C high monocytes are short lived and accumulate at inflammatory sites where they produce reactive oxygen species, nitric oxide, TNF, IL-1b, and type 1 IFN in response to bacterial and viral ligands. These "inflammatory" monocytes can differentiate into dendritic cells or macrophages that are capable of secreting high levels of proinflammatory cytokines TNF and IL-6 in tissue [27] . In fact, splenic EMH preferentially generates Ly6C high monocytes that localize to affected tissues and contribute to the pathologic course of diseases, including cancer and atherosclerosis by increased production of inflammatory mediators [20, 21] . The documented myeloid bias in splenic EMH is believed to be a result of the dominant presence of myeloid growth factors (e.g., GM-CSF) in extramedullary sites [28, 29] . However, proinflammatory cytokines, including type I IFN and TNF, have been shown to stimulate myelopoiesis [30] [31] [32] [33] [34] [35] . In these studies, researchers have examined only short-term exposure, and the effects of sustained inflammation, as observed during chronic inflammatory disease, remain to be explored. Aging is an excellent system for the study of long-term exposure to inflammation, as it is often described as a chronic inflammatory condition [36] . With age, there is an increase in proinflammatory cytokines (i.e., TNF, IL-6, IL-1b, and IFN-g) in circulation and in tissues, referred to as "inflammaging" [37] . There is a concomitant increase in ageassociated diseases (i.e., cardiovascular disease, type II diabetes, cancer, Alzheimer's disease, and chronic lower respiratory disease) driven by increased inflammatory monocytes and macrophages [25, 38] . We have found that there is a TNF-dependent increase in circulating inflammatory monocytes in old mice [39] . Whether the age-associated increase in inflammation drives myelopoiesis and leads to the development of these chronic diseases or the inflammatory diseases themselves establish this chronically inflamed state remains to be explored.
We observed significant splenomegaly in our old mice (.18 mo old), which led us to hypothesize that is a result of EMH. We quantified the cell types, which were increased in the spleens of old mice and found that the increase in myeloid cells and proliferation in the splenic red pulp were consistent with EMH. Because high levels of TNF are associated with myelodysplastic syndrome [31, 40, 41] , which closely mirrors the hematopoietic changes documented with age [42] , we hypothesized that ageassociated increases in TNF drive extramedullary myelopoiesis. To explore this possibility, we examined splenic hematopoiesis in TNF-knockout mice and found that prolonged exposure to TNF contributed to increased splenic myelopoiesis, which was reversible after 3 wk of anti-TNF treatment. Furthermore, using age-discordant bone marrow chimeras, we were able to determine that the increased splenic myelopoiesis was a result of the aging microenvironment.
MATERIALS AND METHODS

Animals
Female WT (C57BL/6) and TNF-KO (B6;129S-Tnf tm1Gkl /J) mice were originally obtained from The Jackson Laboratory (Bar Harbor, ME, USA) and aged inhouse. All mice were housed in pathogen-free conditions in accordance with Institutional Animal Utilization protocols approved by McMaster University's Animal Research Ethics Board, as per the recommendations of the Canadian Council for Animal Care. All animals used were sex matched to their controls and were maintained in the same animal room. The pathogen-free status of mice within the aging colony was confirmed in mice through constitutive monitoring of sentinel mice and specific testing of fecal samples for common mouse pathogens.
Heterochronic bone marrow chimeras
Groups of 10 old (18 mo, C57Bl/6; The Jackson Laboratory) and 10 young (6-8 wk, B6.SJL-Ptprca Pepcb/BoyJ C57Bl/6; Jackson Laboratories) recipient mice were used. Of these, 5 per group received bone marrow from age-matched congenic CD45.1 donors as a control, and 5 per group received CD45.1 age-discordant marrow (e.g., old→young and young→old). Recipients were treated with prophylactic antibiotics for 3 d (e.g., sulfamethoxazole/trimethoprim; Septra, Pfizer, New York, NY, USA) before receiving 2 doses of 550 rads of g irradiation (1100 rads total). Within 2 h of a second irradiation, mice were injected intravenously with 1 3 10 7 cells of T-cell-depleted donor bone marrow (CD90.2 Positive Selection Kit II; cat. no. 18951; StemCell, Vancouver, BC, Canada). Engraftment was determined by ratios of CD45.1 to CD45.2 determined by flow cytometry and was determined to be .95% in all recipients.
In vivo anti-TNF treatment
Adalimumab (Humira; Abbott Laboratories, Arlington Heights, IL, USA), a fully humanized anti-TNF antibody, was used, with human IgG (BioLegend, San Diego, CA, USA) administered to control animals in sterile saline. A dose of 50 ng/g of body weight was given intraperitoneally every other day for 3 wk to young and old WT mice. In total, each mouse received 10 doses of adalimumab or an equal dose of control hIgG.
Histology and immunohistochemistry
Histologic analysis was performed on samples from spleens of old WT and TNF KO mice and the young controls. Upon collection, spleens, livers, and kidneys were fixed in 10% neutral buffered formalin for a minimum of 24 h and were embedded in paraffin. Resultant tissue blocks were cut into 3 mm sections stained with H&E or Ki67 (1:100 dilution; Dako, Carpinteria, CA, USA) at the Core Histology Facility, McMaster Immunology Research Centre. For Ki67 staining, paraffin-embedded sections were deparaffinized, and heatinduced antigen retrieval was performed with Target Retrieval Solution (Dako). Detection was performed with an anti-rat antibody detection system (EnVision+; Dako). Images were acquired with a DM LB2 microscope at a magnification of 310, 320, and 340 and a DFC 280 camera (both from Leica, Bannockburn, IL, USA). The magnification of the eyepiece remained at 310, achieving total magnification of 3100, 3200, and 3400.
Flow cytometry
Single-cell suspensions were prepared by homogenizing spleen tissue through a 40 mm cell strainer or by passing bone marrow from the femurs through an 18-gauge needle. Cells were incubated for 1 h at room temperature with a direct application of antibodies. Monoclonal antibodies with the following specificities were used for monocyte subset differentiation: CCR2 (PE; R&D Systems, Minneapolis, MA, USA) and F4/80 (APC), Ly-6C (FITC), CD45 (eFluor 450), CD11b (PE-Cy7), MHC II (PerCP eFluor 710), and CD3, B220, NK1.1 (Alexa Fluor 700) , all from eBioscience (San Diego, CA, USA). Samples were then incubated with 13 Fix/Lyse Buffer (eBioscience) for 10 min with frequent inversion and centrifuged at room temperature. Samples were washed with sterile PBS and resuspended in 2% paraformaldehyde before flow cytometric analysis and were then run on an LSRII flow cytometer (BD Biosciences, Franklin Lake, NJ, USA) and analyzed with FlowJo 9 software (Treestar, Ashland, OR, USA). Total cell counts were determined with 123 count eBeads (eBioscience). For monocyte gating strategy see Puchta et al. [43] . Monoclonal antibodies with the following specificities were used for analysis of hematopoietic progenitors: Sca-1 (AF700), CD117 (FITC), CD34 (APC), CD16 (PerCP eFluor 710), and Gr-1, CD3, Ter119, B220, and CD11b (PE-Cy7), all from eBioscience, and Ki67 (BV605) from BioLegend. For progenitor gating strategy, see Challen et al. [44] . Intracellular staining for Ki67 was performed after permeabilization with Perm Buffer II (BD Biosciences), as per manufacturer's instructions. The positive gate for Ki67 was set based on isotype control.
Fisher Scientific Life Sciences, CA, USA), all according to the manufacturers' instructions. Cycle threshold (Ct) values relative to the internal reference dye were transformed by a standard curve, followed by normalization to the housekeeping gene GAPDH. Normalized results are presented as relative to an internal calibrator sample. Primer sequences are as follows (F, forward; R, reverse):
Serum TNF
Serum TNF was measured by using Milliplex Mouse Cytokine/Chemokine Magnetic Bead Panel (EMD Millipore, Billerica, MA, USA), according to the manufacturer's instructions.
Statistical analysis
Unless otherwise mentioned in the figure legend, statistical significance was determined by 2-way analysis of variance with Fisher's post hoc test and unpaired 2-tailed t tests. Statistical significance was defined as a P , 0.05. All data were analyzed with Prism (Version 6; GraphPad, San Diego, CA, USA).
RESULTS
Splenomegaly in old mice is a result of extramedullary hematopoiesis
One of the striking phenotypes in our old mice (.18 mo) is splenic enlargement/splenomegaly (Fig. 1A) . We observed distinct changes to the microarchitecture and composition of the spleen in old mice compared to their young counterparts. The size and cellularity of the red pulp, which is the site of hematopoiesis of myeloid precursors, increased, as did the number of megakaryocytes in the subcapsular region of the red pulp, a hallmark of extramedullary hematopoiesis [45] (Fig. 1B) . To confirm that active proliferation was occurring, immunohistochemistry for Ki67, a marker of cellular proliferation, was performed. Cells staining for Ki67 were localized in clusters in the subcapsular regions of the splenic red pulp, in proximity to the megakaryocytes. No signs of extramedullary hematopoiesis were seen in the kidneys or liver (Supplemental Fig. 1 ).
Extramedullary myelopoiesis driven by life-long exposure to TNF
Because proliferation was primarily localized to the red pulp, where monocytosis has been demonstrated to occur, splenic leukocytes were quantified, to determine whether extramedullary hematopoiesis is skewed toward monopoiesis. The total number of the various lymphocytes (B cells, T cells, and NK cells) was the same between young and old mice, whereas myeloid cells (megakaryocytes and monocytes) were significantly increased (Fig. 2) . Because TNF is linked to myeloproliferative conditions and increased in our old mice (young: 1.397 6 0.1931 pg/ml, n = 14; old: 3.447 6 0.7372 pg/ml, n = 30), we examined the splenic phenotype of old TNF KO mice and found that they did not have increased spleen weight with age, nor did the number of megakaryocytes or monocytes increase. There were no differences in spleen size or number of monocytes between young TNF KO and WT mice ( Fig. 2A) .
TNF drives increases in the number and proliferation of splenic myeloid progenitors
The hematopoietic progenitors in the bone marrow and spleens of young and old WT and TNF KO mice were quantified by flow cytometry. Old mice had significantly more CMPs and GMPs than young mice had in the spleen and bone marrow (Fig. 3A-D) . The fold change in number of cells was significantly higher between young and old WT mice in the spleen (GMP, 7-fold increase; CMP, 14-fold increase), in comparison to the bone marrow (GMP, 2.7-fold increase; CMP, 1.78-fold increase). Old TNF KO mice did not have increased CMPs and GMPS with age. In addition, intracellular staining revealed a higher proportion of splenic CMPs, and GMPs were positive for Ki67 in old mice; however, no differences were seen in the CLPs (Fig. 3E-G) . Although we found no differences in the growth factors G-CSF, M-CSF, or GM-CSF to explain the increased number or proliferation of these progenitors (Supplemental Fig. 2 ), we found greater expression of the adhesion molecule VCAM-1 in the spleens of old mice (Fig. 3H ).
TNF neutralization reverses extramedullary myelopoiesis and reduces the number of Ly6C high monocytes in old mice
We noted that, of the 2 monocyte populations (Ly6C high and Ly6C low ) that have been reported in the spleen, Ly6C high "inflammatory" monocytes were more numerous with increasing age. Because we observed that chronic TNF drives extramedullary monopoiesis in our old mice ( Fig. 2A) , we were curious about whether its neutralization would reduce the number of inflammatory monocytes and thus reduce extramedullary monopoiesis. TNF was ablated with anti-TNF, and human IgG was used as a control. Antibodies were administered to young and old mice every other day for 3 wk. As predicted, old mice receiving the anti-TNF treatment displayed complete reversal of splenomegaly and showed decreased monocyte and megakaryocyte counts, indicating decreased extramedullary myelopoiesis (Fig. 4) .
The aging microenvironment drives extramedullary monopoiesis
To determine whether intrinsic changes in the myeloid progenitors themselves or changes in the aging microenvironment drive splenic monopoiesis, age-discordant bone marrow chimeras were created. Bone marrow from either young or old donor mice was transplanted into both young and old recipients. The number of splenic monocytes was higher in old recipient mice, regardless of the age of the bone marrow donor, suggesting that the aging microenvironment drives monopoiesis (Fig. 5A) . Of these monocytes, the proportion of Ly6C high cells increased (Fig. 5B ) in a microenvironment-dependent manner. high monocytes (C) (n = 3-9) and enumeration of megakaryocytes in the subcapsular red pulp (D) (n = 10 high-power fields) showed increased production of myeloid cells with age, which is dependent on TNF. The total number of lymphocytes (E) (n = 3-9) indicate that lymphopoiesis was unchanged in old TNF KO mice. Data represent 1 of 2 independent experiments. *P , 0.05, **P , 0.005, ****P , 0.00005, 1-way ANOVA with Fisher's LSD post hoc test, when appropriate.
DISCUSSION
Our results indicate that, with age, there is increased splenic extramedullary hematopoiesis, giving rise primarily to myeloid cells. Aging is accompanied by many changes to the hematopoietic compartment. Mesenchymal stem cells are instrumental in directing hematopoiesis by differentiating into cell types, such as bone and fat precursors that make up the bone marrow stroma. In the elderly, decreased osteoblast differentiation and red marrow with a concomitant enrichment of adipocytes lead to a distorted niche less conducive to hematopoiesis [46, 47] . It has been proposed that EMH compensates for compromised hematopoiesis in the bone marrow [1] , which could explain the increased splenic EMH in our old mice. What remains to be determined is whether an increase in circulating HSPCs from the bone marrow seed the spleen, or those that have seeded the spleen throughout the lifetime of these animals respond to factors in their microenvironment [48] . Our data indicate there is an age-associated increase in myelopoiesis, because of the greater number of myeloid progenitors (CMPs and GMPs) in the bone marrow and spleens of our old mice. The fold change in the number of progenitors between young and old mice was more pronounced in the spleen. In addition, the proportion of splenic progenitors undergoing proliferation was significantly higher in the old mice. This increased division likely gave rise to the increase in monocytes in the old mice. Our heterochronic chimera study suggests that the splenic progenitors are newly seeded cells, in that native HSPCs are destroyed during irradiation. Mice aged in the absence of TNF were protected from increased monopoiesis, and we concluded from the data that, regardless of the source of these progenitors, TNF from Total number of CMPs and GMPs in the bone marrow and spleen of young (8 wk) and old (22 mo) WT and TNF KO mice showed an age-associated increase in myeloid progenitors that did not occur in the old TNF KO mice. (E-G) Intracellular staining for Ki67 showed that the proportion of CMPs and GMPs actively dividing were higher in the old WT than in the other groups. No differences were seen in the CLPs (n = 3-5). (H) Levels of VCAM-1 transcript in the spleen were measured by quantitative PCR. Expression was normalized to GAPDH and shown relative to the average young WT expression (n = 3-5). *P , 0.05, **P , 0.005, ***P , 0.0005, ****P , 0.00005, 1-way ANOVA with Fisher's LSD post hoc test, when appropriate.
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the aging microenvironment supports production and proliferation of monocytes.
Levels of TNF in the circulation and tissues increase with age [36, 49] ; however, its source is unknown. The strongest evidence to date is that stimulation by chronic viral infections (i.e., Epstein Barr virus and cytomegalovirus) results in the expansion of terminally differentiated, virusspecific effector T cells that produce proinflammatory cytokines [50] . Alternatively, in animal [51] and Drosophila [52] models, microbial translocation caused by impaired intestinal barrier function has been proposed to drive "inflammaging," and this is consistent with observations of increased circulating bacterial products in the elderly [53] . In fact, long-term exposure to low-dose LPS in young mice simulates many of the age-associated changes in hematopoiesis [54] . Furthermore, the chronic inflammation that occurs with age has been shown to alter the MSC compartment and promote the formation of adipocytes [55] [56] [57] [58] [59] [60] , which secrete high amounts of TNF [60] .
TNF is known to inhibit lymphopoiesis [61] , while promoting myelopoiesis [35, 62] . TNF could support monopoiesis by promoting the recruitment, proliferation, or retention of progenitor cells in the spleen. TNF stimulation increases production of growth factors (e.g., G-CSF, GM-CSF, and CSF-1) by fibroblasts, endothelial cells, and monocytes and upregulates receptors for these growth factors [63] . Alternatively, TNF may upregulate growth factor receptors on HSPCs directly. TNF has been shown to act in synergy with G-CSF and IFN-g to upregulate GM-CSFR on DC progenitors [63] and human acute myeloid leukemia cells [64] . Other possible mechanisms could be driven by increased recruitment and retention of monocytes and HSPCs in the spleen. MSCs have been shown to be present in the adult spleen and facilitate EMH in these tissues [65] . When splenic MSCs are stimulated with TNF, they increase production of MCP-1 [66] . Even more striking is that these MSCs do not become refractory upon restimulation with TNF, but produce increased levels of MCP-1 [66] , which could lead to increased recruitment of monocytes to the spleen. We investigated Figure 4 . TNF neutralization reverses splenic monopoiesis in old mice. Young (6-8 wk) and old (18-22 mo) mice were treated with human IgG or anti-TNF (adalimumab) at 50 ng/g body weight every other day for 3 wk. Data are means 6 SEM. Spleen weight (normalized to body weight) (A) (n = 4-5) and total splenic Ly6C high monocytes (B) (n = 5) and megakaryocytes (C) in the subcapsular red pulp (n = 10 high-power fields) showed a decrease in splenomegaly and splenic monopoiesis in old mice receiving anti-TNF therapy. *P , 0.05, **P , 0.005, ****P , 0.00005, 1-way ANOVA with Fisher's LSD post hoc test, when appropriate. Figure 5 . The TNF that drives splenic monopoiesis is derived from the aging microenvironment. Heterochronic bone marrow chimeras were generated with young (6-8 wk) and old (18 mo) mice. Data are means 6 SEM (n = 5). The total number of splenic Ly6C high (A) and Ly6C low (B) monocytes showed that increased monopoiesis occurred in the old host, independent of the age of donor bone marrow. Data represent 1 of 2 independent experiments. *P , 0.05, 1-way ANOVA with Fisher's LSD post hoc test, when appropriate.
whether the increase in splenic monopoiesis was related to the higher production of colony-stimulating factors (M-CSF, G-CSF, or GM-CSF), but saw no differences in transcript levels in the spleen that could explain the phenotype. However, there was an increase in the expression of VCAM-1 in our old mice. VCAM-1 is expressed on splenic macrophages to retain HSPCs [67] and is known to be upregulated by TNF through NFkB activation [68, 69] . Our data are consistent with an ageassociated increase in TNF that drives greater expression of VCAM-1 in the spleen, resulting in higher retention of HSPCs and subsequent proliferation under the influence of the local myeloid-polarizing environment [28] .
Monocytes are key to the propagation of many inflammatory diseases [26] . CCR2 high Ly6C high monocytes are particularly involved in propagating inflammation and have been the target of therapeutic modulation and ablation in these diseases [70, 71] . Most strategies have been to reduce the mobilization and recruitment of monocytes by targeting the chemokine MCP-1 or its receptor CCR2 [70] . Systemic apoptosis-mediated ablation of CCR2 high Ly6C high monocytes after their selective uptake of polystyrene microparticles improved the symptoms and progression of colitis, experimental autoimmune encephalomyelitis, and myocardial infarction [71] . This approach has shown promise; however, concerns have been raised with regard to increasing the risk of infection and impairing the resolution of inflammation and tissue repair [72] . What remains unknown is whether monocytes arising in the spleen are different from those generated in the bone marrow or other extramedullary sites in their potential to instigate and maintain the pathogenesis of chronic inflammatory disease. Modulating the splenic monocyte compartment may have some merit as a potential therapeutic, given that they have been shown to mobilize to affected tissues and contribute to the pathogenesis in atherosclerosis and cancer [20, 21] . For example, Ly6C + splenic monocytes and macrophages were preferentially targeted with lentivirus and resulted in decreased incidence and severity of autoimmune arthritis [73] . In our old mice, 3 wk of treatment with anti-TNF significantly reduced the number of Ly6C high monocytes. The current work highlighted the need to better understand how TNF drives monopoiesis and the potential to modulate TNF to control systemic inflammation and to curb the development of chronic inflammatory diseases. 
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